|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||2.28 - 2.35|
|52 Week Range||1.65 - 5.70|
|PE Ratio (TTM)||-0.44|
|Earnings Date||Nov 1, 2017 - Nov 6, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||3.50|
SAN DIEGO , Sept. 13, 2017 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) announced today that management will present at the 2017 Cantor Fitzgerald Global Healthcare Conference on Wednesday, ...
The Zacks Analyst Blog Highlights: Caladrius Biosciences, Orexigen Therapeutics, Sangamo Therapeutics and Syndax Pharmaceuticals
The biotech industry has shown strength so far this year. The momentum is likely to continue for some time, it's a good idea to pick a few stocks that are unlikely to lose their momentum soon.